Preview

The BIOPHARM

Satisfactory Essays
Open Document
Open Document
743 Words
Grammar
Grammar
Plagiarism
Plagiarism
Writing
Writing
Score
Score
The BIOPHARM
The BIOPHARM-SELTEK NEGOTIATION
7 Step Negotiation Plan
1) Asses the Situation
Annual turnover - $150 million
Developed only one successful compound - Petrocheck which is sold to the oil industry with a present value of between $5-7million
Product can be used in sewage treatment plant with no present value but very lucrative (Opportunity).
We plan to only concentrate on conventional pharmaceuticals
Very hard to sell plant because it is uniquely configured
Plant can be used for making comp chips but highly unlikely manufacturer would buy it
Option 1
Rebuilding plant: 6months, cost 3million and value at 10m and net yield of 7million.
Option 2
Sell the plant to Biopharm as they will keep operating it as a pharmaceutical company to preserve our current workforce which will save the company 1million.
Biopharm has expressed an interest but no prove to show that they have genetically engineered compounds.
2
Sell patent to elf for 4million
Option 4
After one year 50% chance of selling to EXXON for 5million
Both are not interested in plant
Option 5
We prefer to sell patent for 4million to Biopharm and sell plant aswel.
To complete sale, $200000 needs to be paid off by either of us
Financial calculations
Real estate valuation
Building and land: 20,000,000
Market decline (20M * 20%) 4,000,000 --------------
Plant Value 2yrs ago 16,000,000 ----------------
Public Valuation
Plant current value (16m - 4m(assuming 20% decline again)) 12m
Insurance paid by Seltek 8m
2) Goals and Objectives
We need to sell off U.S plant because it barely break even.
The sooner we sell the plant the better. we need to turn our attention to full conventional pharm. manuf. we need to free up funds for other strategic projects we need to sell the plant and the petrocheck patent we desperately need funds to invest in new projects, so selling plant and patent is an immediate priority! NO LEASING!
3) Prioritise Issues (In order of importance)
Option 2

You May Also Find These Documents Helpful

  • Satisfactory Essays

    Biopure case memo

    • 451 Words
    • 2 Pages

    first synthetic product on the market and obtain all of the premiums associated with it. The stability and ease…

    • 451 Words
    • 2 Pages
    Satisfactory Essays
  • Satisfactory Essays

    • The firm will be launching the first commercially available biotech animal in the U.S…

    • 304 Words
    • 2 Pages
    Satisfactory Essays
  • Satisfactory Essays

    Biopol - Chemistry

    • 287 Words
    • 2 Pages

    Biopol is a biopolymer that is an environmentally friendly biodegradable plastic made from renewable resources (made naturally in plants from starch and glucose). Biopol is the brand name for a group of biopolymers often called PHAs or PHBs. The continual use of petroleum to make polymers for plastic will eventually run out and hence Biopol was introduced as a polymer replacement for petroleum. It is made from an organic substance known as Alcaligenes eutrophus which is a microorganism.…

    • 287 Words
    • 2 Pages
    Satisfactory Essays
  • Satisfactory Essays

    Q5 this business model is very risky, the key is to have expertise in identifying the drugs, which were abandoned by the parent companies for any reason. Pharmaceutical companies, after spending millions of dollars in research, don’t typically abandon their product development, unless they are convinced that their product would be a failure, due to variety of reasons. If proper identification can be done, it saves a large chunk of R&D dollars, especially if the drug is in later stages of development.…

    • 533 Words
    • 3 Pages
    Satisfactory Essays
  • Better Essays

    Nucleon Case

    • 1217 Words
    • 5 Pages

    Although we see the benefit to investing in having their own production capability in house, we feel that in the short-term, Nucleon should not overextend itself on its very first drug venture before it is sure that it will be on the fast track to FDA approval. Furthermore, Nucleon would have to deal with the difficulty and costs of procuring the right talent to fill all the holes that will open up in its organizational structure with regards to maintenance, procurement, quality assurance, technical support, logistics, and other functions in order to operate the manufacturing plant.…

    • 1217 Words
    • 5 Pages
    Better Essays
  • Satisfactory Essays

    96 Balance Sheet 2004 2003 Edwards, Inc. has prepared the following comparative balance sheets Cash $198,000 $102,000 for 2003 and 2004: Receivables $106,000 $78,000 2004 2003 Inventory $100,000 $120,000 Prepaid expenses $12,000 $18,000 Cash $ 198,000 $102,000 Plant assets $840,000 $700,000 Receivables 106,000 78,000 Accumulated depreciation $(300,000) $(250,000) Inventory 100,000 120,000 Patent $102,000 $116,000 Prepaid expenses 12,000 18,000 $1,058,000 $884,000 Plant assets 840,000 700,000 Accounts payable $102,000 $112,000 Accumulated depreciation (300,000) (250,000) Accrued liabilities $40,000 $28,000 Patent 102,000 116,000 Mortgage payable $- $300,000 Preferred…

    • 522 Words
    • 3 Pages
    Satisfactory Essays
  • Satisfactory Essays

    Bio Enzyme

    • 467 Words
    • 2 Pages

    Why are there so many different varieties of cheese when the production process is basically the same for all cheeses?…

    • 467 Words
    • 2 Pages
    Satisfactory Essays
  • Better Essays

    However, the pioneer biotechnology invention has to go through regulatory processes and stakeholder’s scrutiny, before it can enter the market. There are ethical concerns over the plant-based medicines and opposition coming from consumer advocates, environmentalists, rice farmers and food safety activists.…

    • 1049 Words
    • 5 Pages
    Better Essays
  • Better Essays

    3. Value of salvage at the end of the life of the project of $14 million.…

    • 872 Words
    • 4 Pages
    Better Essays
  • Good Essays

    • seeing the potential in europe alex took out a european patent - costs $30000…

    • 971 Words
    • 4 Pages
    Good Essays
  • Good Essays

    → dominated by 2 large mutli-national companies ( Siemens water tech and Zenon membrane solutions)…

    • 1498 Words
    • 6 Pages
    Good Essays
  • Satisfactory Essays

    • The firm will be launching the first commercially available biotech animal in the U.S…

    • 789 Words
    • 4 Pages
    Satisfactory Essays
  • Powerful Essays

    Aberlyn Capital

    • 2570 Words
    • 11 Pages

    The venture leasing deal that Aberlyn proposed to RhoMed is an innovative way for RhoMed, a start-up firm, to acquire financing without diluting its equity value and raising debt in the market. Management believes that the firm is more valuable than venture capital firms would believe, and debt financing would be extremely costly since RhoMed doesn’t currently have positive cash flow. For Aberlyn, the main benefits of the transaction are the interest payments paid on the lease and potential to sell the patent for a much higher value than the original $1 Million valuation by RhoMed. However, this is a rather risky investment for Aberlyn. If RhoMed defaults on its payments, Aberlyn uses the patent as collateral and must sell it in the market. Since the patent is highly individualized and therefore may not be commercially feasible, the patent is probably worth less than what Lulu’s valuation suggests.…

    • 2570 Words
    • 11 Pages
    Powerful Essays
  • Powerful Essays

    Biopharma Case Study

    • 1265 Words
    • 6 Pages

    As of 2009, BioPharma is looking to reduce costs across the board. Profits have been steeply declining while production costs are high, especially at its German and Japanese facilities. With exception of India, demand is expected to remain relatively stable for the short-term future, so BioPharma can no longer afford its costly surplus capacity. BioPharma produces and sells two chemicals in bulk. Each plant they currently have is capable of producing both chemicals. They are willing to idle production at the Germany and Japan plants on one or both chemicals in order to reduce costs. They are also willing to reallocate which plant makes how much of each chemical and where they are distributed to.…

    • 1265 Words
    • 6 Pages
    Powerful Essays
  • Satisfactory Essays

    There are a few barriers to market entry. Acquiring qualified chemists for innovation may be a challenge.…

    • 353 Words
    • 2 Pages
    Satisfactory Essays